FDA announces draft guidance on best practices for convening a GRAS panel
The U.S. Food and Drug Administration (FDA) has issued for public comment a draft guidance on best practices to follow when convening a panel of experts to evaluate whether a substance is “generally recognized as safe” (GRAS) under the conditions of its intended use.
Top